anti-VEGFR-3 immunoliposomes

Anti-VEGFR-3 immunoliposomes (also referred to as anti-VEGFR3-ILs-dox) are experimental, targeted nanoparticle-based drug constructs designed for anti-cancer therapy. They are created by inserting anti-VEGFR-3 (Vascular Endothelial Growth Factor Receptor-3) antibody fragments into the lipid bilayer membrane of pegylated liposomal doxorubicin (PLD). This design combines the cytotoxic payload of doxorubicin with the targeting specificity of an anti-VEGFR-3 antibody. The primary biological target is VEGFR-3, which is predominantly expressed on lymphatic endothelial cells and tumor-associated vasculature. By targeting VEGFR-3, the immunoliposomes aim to deplete tumor-associated vasculature through anti-angiogenic and anti-lymphangiogenic mechanisms, leading to tumor starvation. Developed primarily in academic research at the University of Basel, this therapeutic candidate has shown efficacy in preclinical mouse models of human cancer (such as the Rip1Tag2 model), particularly when combined with anti-VEGFR-2 immunoliposomes.

Other names

anti-VEGFR-3 immunoliposomeanti-VEGFR3 immunoliposomeanti-VEGFR 3 immunoliposomeanti-VEGFR3-ILs-doxanti-VEGFR-3-ILs-doxanti-VEGFR 3-ILs-dox